Literature DB >> 25670385

Advances, nuances, and potential pitfalls when exploiting the therapeutic potential of RNA interference.

M Battistella1, P A Marsden.   

Abstract

The discovery of RNA interference (RNAi) holds the potential to alter the paradigm of medical therapeutics. With the ability to selectively silence the function of a gene, RNAi not only provides an indispensable research tool for determining the function of a gene, but also offers potential for the development of novel therapeutics that will inhibit specific genes involved in disease. New concepts in therapeutics have been uncovered through the study of RNAi. Nuances have emerged. For instance, global RNAi pathways can be affected by somatic mutations in cancer and cellular stress, such as hypoxia. Also, viral gene therapy can have unexpected effects on endogenous short noncoding RNA pathways. Therefore, it is important to understand where RNAi therapeutics enter the processing pathways. We highlight the evolving use of RNAi as a new class of therapeutics, such as for amyloidosis, and address some of the anticipated challenges associated with its clinical application.
© 2014 The American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25670385     DOI: 10.1002/cpt.8

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Application of cationized magnetoferritin for magnetic field-assisted delivery of short interfering RNA in vitro.

Authors:  Melánia Babincová; Štefan Durdík; Natália Babincová; Paul Sourivong; Peter Babinec
Journal:  Lasers Med Sci       Date:  2018-05-30       Impact factor: 3.161

2.  Clinical Pharmacology & Therapeutics: the next five years.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2014-12-05       Impact factor: 6.875

Review 3.  Putting the "mi" in omics: discovering miRNA biomarkers for pediatric precision care.

Authors:  Chengyin Li; Rhea E Sullivan; Dongxiao Zhu; Steven D Hicks
Journal:  Pediatr Res       Date:  2022-07-29       Impact factor: 3.953

Review 4.  Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair.

Authors:  Andrea Lolli; Letizia Penolazzi; Roberto Narcisi; Gerjo J V M van Osch; Roberta Piva
Journal:  Cell Mol Life Sci       Date:  2017-04-22       Impact factor: 9.261

5.  Significant Interference with Porcine Epidemic Diarrhea Virus Pandemic and Classical Strain Replication in Small-Intestine Epithelial Cells Using an shRNA Expression Vector.

Authors:  Da Shi; Xiaobo Wang; Hongyan Shi; Jiyu Zhang; Yuru Han; Jianfei Chen; Xin Zhang; Jianbo Liu; Jialin Zhang; Zhaoyang Ji; Zhaoyang Jing; Li Feng
Journal:  Vaccines (Basel)       Date:  2019-11-02

6.  Specific interference shRNA-expressing plasmids inhibit Hantaan virus infection in vitro and in vivo.

Authors:  Yuan-yuan Liu; Liang-jun Chen; Yan Zhong; Meng-xin Shen; Nian Ma; Bing-yu Liu; Fan Luo; Wei Hou; Zhan-qiu Yang; Hai-rong Xiong
Journal:  Acta Pharmacol Sin       Date:  2016-03-14       Impact factor: 6.150

7.  c-Myb regulates transcriptional activation of miR-143/145 in vascular smooth muscle cells.

Authors:  Mark Chandy; Masayoshi Ishida; Eric A Shikatani; Omar El-Mounayri; Lawrence Changsu Park; Talat Afroze; Tao Wang; Philip A Marsden; Mansoor Husain
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.